• Home
  • Abemaciclib 150mg
  • Abemaciclib 150mg

Abemaciclib 150mg

52002

Abemaciclib is used with hormone therapy for HR-positive, HER2-negative early breast cancer when there is a high risk of the cancer coming back after surgery.

It is also used for HR-positive, HER2-negative breast cancer that is locally advanced or has spread, either as a first treatment with an aromatase inhibitor or after earlier hormone therapy with fulvestrant. In some adults whose advanced HR-positive, HER2-negative breast cancer has worsened after hormone therapy and chemotherapy, abemaciclib may be used on its own.

Usual adult dose range: 50mg to 200mg twice daily; many breast cancer regimens start at 150mg twice daily with hormone therapy, or 200mg twice daily when used alone, with lower doses used if side effects occur.

Indications vary by country and change over time; this website contains information for general patient information and should be checked against local prescribing information before clinical use.

Verification Approach: Each indication and usual dose-range sentence was drafted from at least two recognised medicines information sources, usually FDA/DailyMed or an FDA label plus EMA/eMC, MedlinePlus, Mayo Clinic, Cancer Research UK, NCI/ Cancer.gov, or another reputable medicines-information source. Doses are general adult/patient-information ranges and must not be used to prescribe or change treatment.
  • FDA/DailyMed prescribing information and FDA Oncology/Hematology approval notifications.
  • EMA and UK eMC Summary of Product
    Characteristics and patient leaflets where available.
  • NCI Cancer Drug Information/Cancer.gov and Cancer Research UK medicine information where available.
  • MedlinePlus, NHS/NICE, and other national medicines information for non-oncology or immune/respiratory medicines.
  • Peer-reviewed FDA approval summaries or manufacturer regulatory notices for very new, withdrawn, or region-specific
    indications.